Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
Gabrielle Agin-Liebes, Tara C. Malone, Matthew M. Yalch, et al.
Journal of Psychopharmacology (2020) Vol. 34, Iss. 2, pp. 155-166
Closed Access | Times Cited: 266

Showing 1-25 of 266 citing articles:

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 2, pp. 151-158
Open Access | Times Cited: 300
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
Kristoffer A. A. Andersen, Robin Carhart‐Harris, David Nutt, et al.
Acta Psychiatrica Scandinavica (2020) Vol. 143, Iss. 2, pp. 101-118
Closed Access | Times Cited: 259
Single-Dose Psilocybin Treatment for Major Depressive Disorder
Charles L. Raison, Gerard Sanacora, Joshua D. Woolley, et al.
JAMA (2023) Vol. 330, Iss. 9, pp. 843-843
Open Access | Times Cited: 234
Long-term effects of psychedelic drugs: A systematic review
Jacob S. Aday, Cayla M. Mitzkovitz, Emily K. Bloesch, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 113, pp. 179-189
Closed Access | Times Cited: 188
Towards an understanding of psychedelic-induced neuroplasticity
Abigail E. Calder, Gregor Hasler
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 104-112
Open Access | Times Cited: 183
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Kwonmok Ko, Gemma Knight, James Rucker, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 159
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Max Wolff, Ricarda Evens, Lea J. Mertens, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 141
Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review
Nina Schimmers, Joost J. Breeksema, Sanne Y. Smith-Apeldoorn, et al.
Psychopharmacology (2021) Vol. 239, Iss. 1, pp. 15-33
Closed Access | Times Cited: 112
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Kwonmok Ko, Emma I Kopra, Anthony J. Cleare, et al.
Journal of Affective Disorders (2022) Vol. 322, pp. 194-204
Closed Access | Times Cited: 87
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Jordan Sloshower, Patrick D. Skosnik, Hamideh Safi-Aghdam, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 698-706
Closed Access | Times Cited: 86
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Mauro Cavarra, Alessandra Falzone, Johannes G. Ramaekers, et al.
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 71
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yuan Yao, Dan Guo, Tangsheng Lu, et al.
Psychiatry Research (2024) Vol. 335, pp. 115886-115886
Closed Access | Times Cited: 27
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
Friederike Holze, Nirmal Singh, Matthias E. Liechti, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2024) Vol. 9, Iss. 5, pp. 472-489
Open Access | Times Cited: 21
Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial
Jordan Sloshower, Richard J. Zeifman, Jeffrey Guss, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Quantifying Suicide Risk in Prostate Cancer: A SEER-Based Predictive Model
Jiaxiang Du, Fen Zhang, Weinan Zheng, et al.
Journal of Epidemiology and Global Health (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer
Stephen Ross, Gabrielle Agin-Liebes, Sharon L. Lo, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 553-562
Open Access | Times Cited: 98
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
Gabrielle Agin-Liebes, Trevor Forrest Haas, Rafael Lancelotta, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 543-552
Open Access | Times Cited: 96
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 8-21
Open Access | Times Cited: 81
Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States
Alan K. Davis, Gabrielle Agin-Liebes, Megan España, et al.
Journal of Psychoactive Drugs (2021) Vol. 54, Iss. 4, pp. 309-318
Open Access | Times Cited: 70
Dose–response relationships of psilocybin-induced subjective experiences in humans
Tim Hirschfeld, Timo Torsten Schmidt
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 384-397
Open Access | Times Cited: 69
Classic Psychedelic Drugs: Update on Biological Mechanisms
Franz X. Vollenweider, John Smallridge
Pharmacopsychiatry (2022) Vol. 55, Iss. 03, pp. 121-138
Open Access | Times Cited: 67
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice
Jake Payne, Richard Chambers, Paul Liknaitzky
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 416-423
Open Access | Times Cited: 66
Psychedelics and health behaviour change
Pedro J. Teixeira, Matthew W. Johnson, Christopher Timmermann, et al.
Journal of Psychopharmacology (2021) Vol. 36, Iss. 1, pp. 12-19
Open Access | Times Cited: 60
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review
Bruno Roméo, Marianne Hermand, Amélie Petillion, et al.
Journal of Psychiatric Research (2021) Vol. 137, pp. 273-282
Open Access | Times Cited: 59
The therapeutic potential of psilocybin: a systematic review
Jan van Amsterdam, Wim van den Brink
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 833-840
Closed Access | Times Cited: 58
Page 1 - Next Page

Scroll to top